Considering that cisplatin is still one of first-line drugs in treatment of HNSCC56,57 the potential clinical significance of our results would be that knockdown of YY1 might increase efficiency of cisplatin or decrease the amount of cisplatin in treatment of HNSCC. This evidence concerns the gene YY1 and head and neck squamous cell carcinoma.